332 related articles for article (PubMed ID: 11363901)
41. Agouron and immune response to commercialize remune immune-based treatment.
James JS
AIDS Treat News; 1998 Jun; (No 297):1. PubMed ID: 11365593
[TBL] [Abstract][Full Text] [Related]
42. Remune rejected. (will a manual recount be required?).
Martinez LJ
Res Initiat Treat Action; 2000 Dec; 6(4):23-4. PubMed ID: 11708171
[No Abstract] [Full Text] [Related]
43. Salk's HIV immunogen: an immune-based therapy in human trials since 1988.
Crit Path AIDS Proj; 1994-1995 Winter; (No 30):1, 20-3. PubMed ID: 11362152
[TBL] [Abstract][Full Text] [Related]
44. Use and access to viral load measure assays: the need for validation.
Agosto M
Update Natl Minor AIDS Counc; 1995; ():7-8. PubMed ID: 11362791
[TBL] [Abstract][Full Text] [Related]
45. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I;
J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661
[TBL] [Abstract][Full Text] [Related]
46. Therapeutic HIV vaccine from Spain.
Burton A
Lancet Infect Dis; 2001 Dec; 1(5):291. PubMed ID: 11871794
[No Abstract] [Full Text] [Related]
47. Clinical trials of HIV treatment begin in Thailand.
AIDS Wkly Plus; 1996 Apr 8-15; ():14. PubMed ID: 12320053
[TBL] [Abstract][Full Text] [Related]
48. Salk therapy begins.
Posit Aware; 1996; 7(3):7. PubMed ID: 11363429
[TBL] [Abstract][Full Text] [Related]
49. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
[TBL] [Abstract][Full Text] [Related]
50. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization.
Kran AM; Sommerfelt MA; Sørensen B; Nyhus J; Baksaas I; Bruun JN; Kvale D
Vaccine; 2005 Jul; 23(31):4011-5. PubMed ID: 15963359
[TBL] [Abstract][Full Text] [Related]
51. New study on viral load.
Posit Aware; 1996; 7(1):5. PubMed ID: 11363123
[TBL] [Abstract][Full Text] [Related]
52. Public health rationale for rapid nucleic acid or p24 antigen tests for HIV.
Pilcher CD; Christopoulos KA; Golden M
J Infect Dis; 2010 Apr; 201 Suppl 1():S7-15. PubMed ID: 20225950
[TBL] [Abstract][Full Text] [Related]
53. Inactivated HIV-1 Immunogen: impact on markers of disease progression.
Moss RB; Ferré F; Trauger R; Jensen F; Daigle A; Richieri SP; Carlo DJ
J Acquir Immune Defic Syndr (1988); 1994; 7 Suppl 1():S21-7. PubMed ID: 7910207
[TBL] [Abstract][Full Text] [Related]
54. The Effect of Therapeutic HIV Vaccination With ALVAC-HIV With or Without Remune on the Size of the Viral Reservoir (A CTN 173 Substudy).
Angel JB; Routy JP; Graziani GM; Tremblay CL
J Acquir Immune Defic Syndr; 2015 Oct; 70(2):122-8. PubMed ID: 26375464
[TBL] [Abstract][Full Text] [Related]
55. Outcomes of a trial of HIV-1 immunogen in patients with HIV infection.
Dat NV
JAMA; 2001 May; 285(17):2191; 2193-5. PubMed ID: 11325312
[No Abstract] [Full Text] [Related]
56. HIV-1 Immunogen: an overview of almost 30 years of clinical testing of a candidate therapeutic vaccine.
Graziani GM; Angel JB
Expert Opin Biol Ther; 2016 Jul; 16(7):953-66. PubMed ID: 27266543
[TBL] [Abstract][Full Text] [Related]
57. Report from the 12th Retrovirus Conference. Immune-based therapies for established HIV infection.
Henry K
AIDS Clin Care; 2005 Apr; 17(4):35-6. PubMed ID: 15877316
[No Abstract] [Full Text] [Related]
58. The use of pentoxifylline alone in HIV-infected patients.
Mole L; Margolis D; Ghotbi L; Holodniy M
J Acquir Immune Defic Syndr (1988); 1994 May; 7(5):519-21. PubMed ID: 7908984
[No Abstract] [Full Text] [Related]
59. Durable Control of HIV Infection in the Absence of Antiretroviral Therapy: Opportunities and Obstacles.
Chun TW; Eisinger RW; Fauci AS
JAMA; 2019 Jul; 322(1):27-28. PubMed ID: 31169893
[No Abstract] [Full Text] [Related]
60. Remune vaccine trial halted; study design flaws cited.
Slovick J
Posit Living; 2000 Jul; 9(6):21, 55. PubMed ID: 12492016
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
